Implantable drug delivery systems (IDDS) are an attractive alternative to conventional drug
administration routes. Oral and injectable drug administration are the most common routes …

Introduction Antipsychotic medications are mainstays in the treatment of schizophrenia and
a range of other psychotic disorders. Sources of data Recent meta-analyses of antipsychotic …

Background Major psychiatric disorders are growing public health concern that attributed
14% of the global burden of diseases. The management of major psychiatric disorders is …

Adherence to antipsychotics improves outcome in schizophrenia. There is a lack of
consensus on which factors most influence adherence behaviour and methodological …

Background Long-acting injectable (LAI) antipsychotics, compared with oral antipsychotics
(OA), have been found to significantly improve patient outcomes, including reduced …

Schizophrenia is a debilitating illness with a lifetime prevalence estimate of 0.6% and
consists of symptoms from the positive, negative, and cognitive domains. Social support …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …

The large majority of individuals with a first episode of schizophrenia will experience a
remission of symptoms within their first year of treatment. It is not clear how long treatment …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

Medication nonadherence is common among patients with schizophrenia and due to a
variety of factors including lack of insight, psychopathology, substance use disorder, issues …